Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis

BMC Musculoskeletal Disorders

Volumn 18, Issue 1, 2017, Pages

  Wang, Shi Qin ^a   Zhang, Li Wei ^a   Wei, Pan ^a   Hua, Hong ^a  

^a PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

Author keywords

Hydroxychloroquine; Meta analysis; Sjogren's syndrome; Systematic review

Indexed keywords

HYDROXYCHLOROQUINE; PLACEBO; ANTIRHEUMATIC AGENT;

ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL ASSESSMENT; COCHRANE LIBRARY; DESCRIPTIVE RESEARCH; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EMBASE; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; OVID; PAIN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SCHIRMER TEST; SICCA SYMPTOM; SIDE EFFECT; SJOEGREN SYNDROME; SYMPTOM; WEB OF SCIENCE; XEROSTOMIA; PROCEDURES; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; HUMANS; HYDROXYCHLOROQUINE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 85018904378     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-017-1543-z     Document Type: Article

References (52)

1. Greenspan JS, Daniels TE, Talal N, Sylvester RA. The histopathology of Sjogren's syndrome in labial salivary gland biopsies. Oral Surg Oral Med Oral Pathol. 1974;37(2):217-29.
2. Fox PC. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007;1098:15-21.
3. Espitia-Thibault A, Masseau A, Neel A, Espitia O, Toquet C, Mussini JM, Hamidou M. Sjogren's syndrome-associated myositis with germinal centre-like structures. Autoimmun Rev. 2017;16(2):154-8.
4. Bolstad AI, Skarstein K. Epidemiology of Sjogren's Syndrome-from an Oral Perspective. Curr Oral Health Rep. 2016;3(4):328-36.
5. ter Borg EJ, Risselada AP, Kelder JC. Relation of systemic autoantibodies to the number of extraglandular manifestations in primary Sjogren's Syndrome: a retrospective analysis of 65 patients in the Netherlands. Semin Arthritis Rheum. 2011;40(6):547-51.
6. Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, Gattamelata A, Maset M, Modesti M, Tavoni A, et al. Primary Sjogren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology (Oxford, England). 2014;53(5):839-44.
7. Ramos-Casals M, Brito-Zeron P, Seror R, Bootsma H, Bowman SJ, Dorner T, Gottenberg JE, Mariette X, Theander E, Bombardieri S, et al. Characterization of systemic disease in primary Sjogren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford, England). 2015;54(12):2230-8.
8. Fox RI. Sjogren's syndrome. Lancet (London, England). 2005;366(9482):321-31.
9. Drosos AA, Andonopoulos AP, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM. Prevalence of primary Sjogren's syndrome in an elderly population. Br J Rheumatol. 1988;27(2):123-7.
10. Venables PJ. Sjogren's syndrome. Best Pract Res Clin Rheumatol. 2004;18(3):313-29.
11. Chiorini JA, Cihakova D, Ouellette CE, Caturegli P. Sjogren syndrome: advances in the pathogenesis from animal models. J Autoimmun. 2009;33(3-4):190-6.
12. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, Zhong R. Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(11):1983-9.
13. Goules AV, Tzioufas AG. Primary Sjgren's syndrome: Clinical phenotypes, outcome and the development of biomarkers. Autoimmun Rev. 2016;15(7):695-703.
14. Liang Y, Yang Z, Qin B, Zhong R. Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2014;73(6):1151-6.
15. Bostrom EA, d'Elia HF, Dahlgren U, Simark-Mattsson C, Hasseus B, Carlsten H, Tarkowski A, Bokarewa M. Salivary resistin reflects local inflammation in Sjogren's syndrome. J Rheumatol. 2008;35(10):2005-11.
16. Forsblad-d'Elia H, Carlsten H, Labrie F, Konttinen YT, Ohlsson C. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. J Clin Endocrinol Metab. 2009;94(6):2044-51.
17. Nikolov NP, Illei GG. Pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol. 2009;21(5):465-70.
18. Roescher N, Tak PP, Illei GG. Cytokines in Sjogren's syndrome: potential therapeutic targets. Ann Rheum Dis. 2010;69(6):945-8.
19. Alunno A, Carubbi F, Bartoloni E, Bistoni O, Caterbi S, Cipriani P, Giacomelli R, Gerli R. Unmasking the pathogenic role of IL-17 axis in primary Sjogren's syndrome: a new era for therapeutic targeting? Autoimmun Rev. 2014;13(12):1167-73.
20. Mackay F, Groom JR, Tangye SG. An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol. 2007;19(5):406-13.
21. Verstappen GM, Kroese FG, Meiners PM, Corneth OB, Huitema MG, Haacke EA, van der Vegt B, Arends S, Vissink A, Bootsma H, et al. B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjogren Syndrome. J Rheumatol. 2017;44(1):49-58.
22. Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H et al. Treatment Guidelines for Rheumatologic Manifestations of Sjogren's: Use of Biologics, Management of Fatigue and Inflammatory Musculoskeletal Pain. Arthritis Care Res. 2017;69(4):517-27.
23. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. Jama. 2010;304(4):452-60.
24. Valim V, Trevisani VF, Pasoto SG, Serrano EV, Ribeiro SL, Fidelix TS, Vilela VS, Prado LL, Tanure LA, Liborio-Kimura TN, et al. Recommendations for the treatment of Sjogren's syndrome. Rev Bras Reumatol. 2015;55(5):446-57.
25. Cornec D, Jamin C, Pers JO. Sjogren's syndrome: where do we stand, and where shall we go? J Autoimmun. 2014;51:109-14.
26. Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjogren syndrome. Nat Rev Rheumatol. 2016;12(8):456-71.
27. Goodman SM. Rheumatoid arthritis: Perioperative management of biologics and DMARDs. Semin Arthritis Rheum. 2015;44(6):627-32.
28. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231-69.
29. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-8.
30. Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for rheumatoid arthritis. Cochrane Database of Syst Revi. 2000;(2):Cd000959.
31. Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5 Suppl 1:S31-6.
32. Tishler M, Yaron I, Shirazi I, Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58(4):253-6.
33. Mumcu G, Bicakcigil M, Yilmaz N, Ozay H, Karacayli U, Cimilli H, Yavuz S. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjogren's syndrome. Oral Health Prev Dent. 2013;11(3):229-34.
34. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ (Clin Res Ed). 2012;344:e3821.
35. Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjogren's syndrome. Nat Rev Rheumatol. 2012;8(7):399-411.
36. Gottenberg JE, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P, Dubost JJ, Fauchais AL, Goeb V, Hachulla E, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One. 2013;8(5):e59868.
37. Kruize AA, Hene RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360-4.
38. Cankaya H, Alpoz E, Karabulut G, Guneri P, Boyacioglu H, Kabasakal Y. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjogren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(1):62-7.
39. Gottenberg JE, Ravaud P, Puechal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial. Jama. 2014;312(3):249-58.
40. Yoon CH, Lee HJ. Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjogren's Syndrome: a Double-Blind Randomized Control Study. J Korean Med Sci. 2016;31(7):1127-35.
41. Vivino FB, Carsons SE, Foulks G, Daniels TE, Parke A, Brennan MT, Forstot SL, Scofield RH, Hammitt KM. New Treatment Guidelines for Sjogren's Disease. Rheum Dis Clin N Am. 2016;42(3):531-51.
42. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clin Res Ed). 2015;349:g7647.
43. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-84.
44. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
45. Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951-7.
46. Heaton JM. The treatment of Sjogren's syndrome with hydroxychloroquine. Am J Ophthalmol. 1963;55:982-6.
47. Senecal JL, Chartier S, Rothfield N. Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine. J Rheumatol. 1995;22(5):868-75.
48. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5 Suppl 1:S4-S10.
49. Pillemer SR, Pando J, Magno B, Kurrasch R, Atkinson J, Macynski A, Fox P. Hydroxychloroquine for Sjogren's syndrome: A double-blind placebo controlled pilot trial. Arthritis Rheum. 1997;40(9 SUPPL):S203.
50. Oxholm P, Prause JU, Schiodt M. Rational drug therapy- Recommendations for the treatment of patients with Sjogren's syndrome. Drugs. 1998;56(3):345-53.
51. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjogren's syndrome with hydroxychloroquine. Am J Med. 1988;85(4a):62-7.
52. Yavuz S, Asfuroglu E, Bicakcigil M, Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. Rheumatol Int. 2011;31(8):1045-9.